Month: April 2024

Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer

by on April 25, 2024

Neha Krishnamohan brings extensive experience across strategic growth, business development, M&A and financing Jennifer Bush, Esq., who brings 14 years of executive leadership, has been promoted to Chief Operating Officer  SAN DIEGO, April 24, 2024 — Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver broadly accessible, off-the-shelf natural killer (NK) cell-based therapies…

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

by on April 17, 2024

To Artiva’s knowledge, this marks the first patient to receive an allogeneic, off-the-shelf NK cell therapy in a U.S. clinical trial for treatment of an autoimmune disease Data demonstrated AlloNK drove deep depletion of peripheral B-cells and complete responses in relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL) patients in ongoing clinical trial, supporting potential mechanism of…